Pharmafile Logo
Pharmafocus logo
Advanced Search

Ilaris

Showing 6 posts of 6 posts found.

novartis_side_building

Novartis targets specific patient population with strong Ilaris Phase 3 data

November 14, 2017
Manufacturing and Production, Research and Development Ilaris, Novartis, cardiovascular, heart attack, heart disease, pharma

Novartis has presented new Phase 3 data on its cardiovascular drug Ilaris (canakinumab) which demonstrate particular efficacy in a specific …

News

EU approval for Ilaris

March 4, 2013
Sales and Marketing Ilaris, Novartis

Novartis’ Ilaris has become the first biologic approved by the European Commission to treat patients suffering acute gouty arthritis attacks …

News

FDA wants more information on Novartis arthritis drug

August 31, 2011
Sales and Marketing FDA, Ilaris, Novarits, canakinumab

The FDA has asked Novartis for more information on its gouty arthritis drug canakinumab. The regulator’s request came in a …

News
Novartis

FDA rejects Novartis’ Ilaris for gouty arthritis

June 22, 2011
Research and Development Ilaris, Novartis, gouty arthritis

An FDA advisory panel has voted against backing Novartis’ Ilaris for gouty arthritis because of safety concerns. Ilaris (canakinumab) is …

News

NICE to appraise hep C drugs Victrelis and telaprevir

May 26, 2011
Sales and Marketing Brinavess, Ilaris, NICE, Victrelis, Xarelto, Zytiga, telaprevir

NICE’s next round of drug appraisals is set to include two new hepatitis C drugs – Merck Sharpe and Dohme’s …

News

Novartis launches Ilaris in the UK

January 12, 2010
Sales and Marketing Ilaris, Novartis, cryopyrin-associated periodic syndrome

Novartis has launched its new biologic Ilaris in the UK as a treatment for cryopyrin-associated periodic syndrome. The rare debilitating …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026